MEDIVIR B news, videos and press releases
For more news please use our advanced search feature.
MEDIVIR B - More news...
MEDIVIR B - More news...
- Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles
- Medivir to present at the Pareto Securities Healthcare Conference
- Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study
- Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA
- Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima
- Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC
- Medivir to present at the Erik Penser Bank Company Event
- MEDIVIR AB - INTERIM REPORT JANUARY - JUNE 2023
- Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included
- Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council
- Medivir's patent application for fostrox approved in China
- Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima
- Medivir to present at the Redeye Growth Day
- Change in the number of shares and votes in Medivir AB (publ)
- Medivir to present at the ABGSC Life Science Summit
- Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2023
- Execution of the annual general meeting's resolution on the removal of share class in Medivir AB (publ)
- Resolutions at the Annual General Meeting in Medivir on 4 May 2023
- MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2023
- Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination
- Medivir 2022 Annual Report published
- Notice of Annual General Meeting of Medivir AB (publ)
- Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACR
- First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with Lenvima®
- Medivir to present at the Stockholm Corporate Finance Life Science Day
- Medivir to present at the Erik Penser Bank Healthcare Day
- Pia Baumann takes up her position as Chief Medical Officer
- Medivir has determined the recommended phase 2 dose for fostrox in combination with Lenvima in HCC
- MEDIVIR AB - YEAR-END REPORT JANUARY - DECEMBER 2022
- Medivir to present at the Redeye Fight Cancer Day